Convoy Therapeutics Inc.
Delivering large molecule dermatology drugs through the skin
This article was originally published in Start Up
Convoy Therapeutics Inc.’s SPACE platform for delivering large molecule drugs through the skin is based on a class of peptides that associate with keratin proteins, and the peptides get passed from one to the other until they diffuse across the outer layer of skin. The peptides can be formulated to envelop drug molecules. Convoy is using drugs that are already FDA approved, and because they have not been chemically modified, the FDA will not require additional clinical trials. The company’s first product delivers the immune-modulating drug cyclosporine for the treatment of moderate to severe psoriasis.
You may also be interested in...
Biologics for psoriasis leapfrogged existing treatments in the last decade, greatly improving the standard of care. Although those may still see incremental improvements, the real changes for patient care may come with the introduction of new oral and topical treatments. START-UP profiles four emerging companies that are tackling this challenge: Avexxin, Cellceutix, Creabilis, and Convoy Therapeutics.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.